These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 29071472)

  • 1. Immune Interventions to Eliminate the HIV Reservoir.
    Hsu DC; Ananworanich J
    Curr Top Microbiol Immunol; 2018; 417():181-210. PubMed ID: 29071472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
    Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
    J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction.
    Yang H; Wallace Z; Dorrell L
    Front Immunol; 2018; 9():2861. PubMed ID: 30564246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
    Sung JA; Pickeral J; Liu L; Stanfield-Oakley SA; Lam CY; Garrido C; Pollara J; LaBranche C; Bonsignori M; Moody MA; Yang Y; Parks R; Archin N; Allard B; Kirchherr J; Kuruc JD; Gay CL; Cohen MS; Ochsenbauer C; Soderberg K; Liao HX; Montefiori D; Moore P; Johnson S; Koenig S; Haynes BF; Nordstrom JL; Margolis DM; Ferrari G
    J Clin Invest; 2015 Nov; 125(11):4077-90. PubMed ID: 26413868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.
    Sloan DD; Lam CY; Irrinki A; Liu L; Tsai A; Pace CS; Kaur J; Murry JP; Balakrishnan M; Moore PA; Johnson S; Nordstrom JL; Cihlar T; Koenig S
    PLoS Pathog; 2015; 11(11):e1005233. PubMed ID: 26539983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules.
    Pollara J; Edwards RW; Jha S; Lam CK; Liu L; Diedrich G; Nordstrom JL; Huffman T; Pickeral JA; Denny TN; Permar SR; Ferrari G
    Front Immunol; 2020; 11():713. PubMed ID: 32373131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which therapeutic strategy will achieve a cure for HIV-1?
    Cillo AR; Mellors JW
    Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells.
    Kong D; Wang Y; Ji P; Li W; Ying T; Huang J; Wang C; Wu Y; Wang Y; Chen W; Hao Y; Hong K; Shao Y; Dimitrov DS; Jiang S; Ma L
    AIDS; 2018 Aug; 32(13):1749-1761. PubMed ID: 29762173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Antiviral Immune Response and Its Impact on the HIV-1 Reservoir.
    Veenhuis RT; Blankson JN
    Curr Top Microbiol Immunol; 2018; 417():43-67. PubMed ID: 29071476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.
    Rochat MA; Schlaepfer E; Speck RF
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockage of CD59 Function Restores Activities of Neutralizing and Nonneutralizing Antibodies in Triggering Antibody-Dependent Complement-Mediated Lysis of HIV-1 Virions and Provirus-Activated Latently Infected Cells.
    Yang K; Lan J; Shepherd N; Hu N; Xing Y; Byrd D; Amet T; Jewell C; Gupta S; Kounga C; Gao J; Yu Q
    J Virol; 2015 Sep; 89(18):9393-406. PubMed ID: 26136568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies.
    Carrillo J; Clotet B; Blanco J
    Front Immunol; 2018; 9():2429. PubMed ID: 30405624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors.
    Yang H; Buisson S; Bossi G; Wallace Z; Hancock G; So C; Ashfield R; Vuidepot A; Mahon T; Molloy P; Oates J; Paston SJ; Aleksic M; Hassan NJ; Jakobsen BK; Dorrell L
    Mol Ther; 2016 Nov; 24(11):1913-1925. PubMed ID: 27401039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Dendritic Cells in Exposing Latent HIV-1 for the Kill.
    Kristoff J; Rinaldo CR; Mailliard RB
    Viruses; 2019 Dec; 12(1):. PubMed ID: 31905690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing Virion Tethering by BST2 Sensitizes Productively and Latently HIV-infected T cells to ADCC Mediated by Broadly Neutralizing Antibodies.
    Pham TN; Lukhele S; Dallaire F; Perron G; Cohen ÉA
    Sci Rep; 2016 Nov; 6():37225. PubMed ID: 27853288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attacking Latent HIV with convertibleCAR-T Cells, a Highly Adaptable Killing Platform.
    Herzig E; Kim KC; Packard TA; Vardi N; Schwarzer R; Gramatica A; Deeks SG; Williams SR; Landgraf K; Killeen N; Martin DW; Weinberger LS; Greene WC
    Cell; 2019 Oct; 179(4):880-894.e10. PubMed ID: 31668804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection.
    Ferrari G; Pollara J; Tomaras GD; Haynes BF
    J Infect Dis; 2017 Mar; 215(suppl_3):S152-S159. PubMed ID: 28520963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies for Human Immunodeficiency Virus-1 Cure Strategies.
    Rossignol E; Alter G; Julg B
    J Infect Dis; 2021 Feb; 223(12 Suppl 2):22-31. PubMed ID: 33586772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy.
    Tsai A; Irrinki A; Kaur J; Cihlar T; Kukolj G; Sloan DD; Murry JP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28179531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.
    Walker-Sperling VE; Cohen VJ; Tarwater PM; Blankson JN
    J Virol; 2015 Sep; 89(18):9631-8. PubMed ID: 26178987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.